{"id":"W2593047881","doi":"10.1111/jdv.14211","title":"Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health; Queen's University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Dermatology Life Quality Index; Post-hoc analysis; Minimal clinically important difference; Clinical endpoint; Placebo; Hazard ratio; Randomization; Randomized controlled trial; Quality of life (healthcare); Internal medicine; Confidence interval; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005071043,0.0003790921,0.003089756,0.0003116878,0.0002499432,0.00001558199,0.0004257549,0.0004616066,0.000006605469],"category_scores_gemma":[0.00446748,0.0002316849,0.0002485403,0.00009987093,0.001269157,0.0001878072,0.0002174707,0.0005813335,0.000002741749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004673649,"about_ca_system_score_gemma":0.0001844399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005697318,"about_ca_topic_score_gemma":0.00009351582,"domain_scores_codex":[0.9861256,0.0100745,0.00286985,0.0004082481,0.00008680983,0.0004350216],"domain_scores_gemma":[0.9888514,0.005364459,0.005319999,0.0003107674,0.00005544549,0.00009789226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1482248,0.003341804,0.6954913,0.0004345155,0.01144881,0.0004482402,0.0134246,0.00005415775,0.03448061,0.001330849,0.002140195,0.08918008],"study_design_scores_gemma":[0.5989521,0.0008024771,0.3730036,0.0004227888,0.0007824319,0.001238359,0.0008486321,0.00002409926,0.01778023,0.002146209,0.003847671,0.0001514821],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967355,0.029288,0.000008975266,0.001728275,0.0003764989,0.0005858194,0.0001524745,0.000006624894,0.0004983966],"genre_scores_gemma":[0.988637,0.01073416,0.0001011435,0.0001976737,0.0000427444,0.000008009669,0.00002156852,0.00002159125,0.0002360847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4507272,"threshold_uncertainty_score":0.9447836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.055895265232394,"score_gpt":0.3162650381622829,"score_spread":0.2603697729298889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}